Sarepta Therapeutics (SRPT) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.64
- Estimate
- $0.50
- Surprise
- +27.6%
- Revenue (period 2026-06-30)
- $328.7M
- Score at report (before → after)
- 5.0 → 5.1/10
Revenue source: xbrl.
How the report landed
Sarepta Therapeutics (SRPT) beat the $0.50 estimate with adjusted EPS of $0.64 — a large 27.6% upside surprise. TrendMatrix's engine moved from Buy (Wait) (5.0/10) to Hold at 5.1/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates SRPT Sell at 5.4/10.
3 of the last 4 quarters beat the estimate; this quarter's +27.6% surprise compares with a -16.6% four-quarter average. Next scheduled report: 2026-11-05.
What argues against it
- Concentration risk — Product: Duchenne products
- Concentration risk — Supplier: Catalent
- Target reached (0.8% upside)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $19.32
- Price target
- $19.47
- Stop
- $17.97
- Upside to target
- +0.8%
- Reward-to-risk
- 0.1:1
Model outputs from TrendMatrix’s engine as of 2026-10-29 — shown for context, not personalized investment advice.
SRPT at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $2.04B
- P/E (fwd)
- 7.9
- 52-week range
- $14.68–$24.68
- Off 52-week high
- 21.7%
- RSI (14)
- 56
- Volume vs avg
- 0.46×
- Score today
- 5.4/10